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DESCRIPTION
A 52-year-old patient had basal cell carcinoma diagnosed by biopsy
on the left side of his nose. In lieu of deﬁnitive surgery to remove
the tumor, the patient elected to use a topical herbal treatment with
NEXTSanguinariacandensis(bloodroot).Whilethisledtoanapparentclinical
resolution of the cancer, the patient returned 11 years later with deep-
seated disease in the same region, which also involved the maxilla. The
lesion was removed by a total rhinectomy and partial maxillectomy;
reconstruction was achieved with a septal mucosal ﬂap and vertical
paramedian forehead ﬂap.
One year subsequently, the patient presented with submandibular
lymphadenopathy. A modiﬁed radical neck lymphadenectomy was per-
formed and cervical lymph nodes were positive for metastatic basaloid
carcinoma.Despitetreatmentwithadjuvantsystemicchemotherapy,the
patient developed rapid distant bony metastasis and died shortly after.
NEXT BACKQUESTIONS
1. What is the metastatic risk of basal cell carcinoma?
2. What are the treatment options for metastatic basal cell carcinoma?
3. How may self-treatment of skin malignancy place the patient at risk for
metastatic spread of disease?
NEXT BACKDISCUSSION
Basal cell carcinoma is the most common skin malignancy, accounting for
up to 80% of all cancers arising from the epidermis.1 Basal cell carcinoma
affects approximately 1 million Americans each year, more than squamous
cell carcinoma and melanoma combined.2 Surgical excision has long been
considered the gold standard of treatment. Surgical excision is generally cura-
tive with 5-year cure rates of more than 99% for primary tumors not involving
the head.3 For lesions involving the head, the 5-year cure rate is 97% for
lesions less than 6 mm and 92% for lesions greater than 6 mm. Other surgical
options include Mohs micrographic surgery, curettage and electrodessication,
and cryosurgery. In a Cochrane review of different treatment modalities, one
study showed no signiﬁcant difference between Mohs micrographic surgery
and surgical excision in recurrence rates at 30 months for high-risk facial
basal cell carcinomas.4
While the lifetime risk of basal cell carcinoma is high, it is well known
to physicians that metastasis is relatively rare. Using the criteria proposed
by Lattes and Kessler5 in 1951, studies have indexed a metastasis rate of
0.0028% to 0.5%.6 Since 1894, there have been around 300 reported cases.7
Wadhera et al6 felt the currently published rate of metastasis underestimated
the metastatic risk. In a review by Randle,8 tumors with any of the following
characteristics should be considered high-risk for metastatic potential: long
duration, location in the mid face or ear, diameter larger than 2 cm, aggressive
histological subtype, previous treatment, neglected, or history of radiation.8
There is a 2% incidence of metastasis for tumors larger than 3 cm in diameter.
The incidence increases to 25% for tumors larger than 5 cm in diameter and
50% for tumors larger than 10 cm in diameter.9 Increased tissue invasion
and extension of the tumor into adjacent anatomical structures also enhance
metastatic potential.9 Immunosuppression and evidence of perineural spread
or invasion of blood vessels have also been implicated as risk factors for
metastasis.10
For patients with metastatic disease, morbidity and mortality remain ex-
ceedingly high. The biggest risk factors for metastasis are tumor size, depth,
and recurrence, despite optimal treatment. Primary basal cell carcinoma
metastasizes usually via lymphatics, although it also spreads hematogenously.
Metastasismostcommonlyoccursinregionallymphnodes,lung,andboneal-
though there have been documented cases involving the spinal cord,11 parotid
gland,12 skin,13 bonemarrow,spleen,liver,adrenalglands,14 brain,duramater,
esophagus, heart, and kidney.15 The prognosis for these patients is poor with
a mean survival time of only 8 months from the time at diagnosis.16 In cases
where metastasis is only to lymph nodes, patients live up to an average of
NEXT BACK3.6 years.17 There has been one reported case in which a patient lived 25 years
after diagnosis.18 Median age at the ﬁrst sign of metastasis is 59 years, while
the median interval between the onset of the primary tumor and the ﬁrst sign
of metastasis is 9 years.6
Therearecurrentlynoestablishedguidelinesforthetreatmentofmetastatic
disease namely because all forms of treatment thus far have provided dismal
results. Systemic chemotherapy has been attempted with mixed results. Com-
binationsof5-ﬂuorouracil,bleomycin,andmethotrexatehavebeenunsuccess-
ful thus far.19,20 However, there has been one case with a positive response
to cyclophosphamide and cis-diamine dichloroplatinum in a patient with pul-
monary metastasis.21 Cisplatin-based therapy for patients with evidence of
metastasis has also been shown to be of some beneﬁt.22-24
The incidence of basal cell carcinoma will continue to increase over the
years as the baby-boomer generation continues to age. In some cases, patients
will try to self-treat the tumor with alternative medicine, such as our patient
who used bloodroot.25 With the advent of the Internet and an unregulated
herbal therapeutic industry, patients will continue to present physicians after
the use of these anecdotally supported treatments.26 We discourage the use
of these forms of treatment, especially within the current culture of practic-
ing evidence-based medicine. Plastic surgeons need to be aware of the poor
prognosisthatmetastaticbasalcellcarcinomacarries.Becauseadequatetreat-
ments are not available for metastasis, prevention should be practiced by all
providers through vigilant monitoring of suspicious skin lesions and early
surgical excision of primary tumors.
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